CA2938818C — Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
Assigned to Astellas Pharma Inc · Expires 2023-03-07 · 3y expired
What this patent protects
[Problem] Provided are a pharmaceutical composition for treating AXL-related cancer, in another aspect, a pharmaceutical composition for treating cancer with high expression of AXL, and in still another aspect, a pharmaceutical composition for treating cancer which has acquired r…
USPTO Abstract
[Problem] Provided are a pharmaceutical composition for treating AXL-related cancer, in another aspect, a pharmaceutical composition for treating cancer with high expression of AXL, and in still another aspect, a pharmaceutical composition for treating cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent. [Means of Solution] The present inventors have studied on compounds having an AXL inhibitory action, and have found that specific diamino heterocyclic carboxamide compounds have an AXL inhibitoty action, and pharmaceutical compositions comprising these compounds as an active ingredient have a therapeutic effect on AXL-related cancer, in another aspect, cancer with high expression of AXL, and in a still another aspect, cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent, thereby completing the present invention.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.